The University of Lausanne is offering this technology for licensing or for collaboration.

The technology allows the prognostic, diagnosis and treatment of Alzheimer disease

Development Phase :
Proof of principle

Patent Status :
A European patent application has been filed on July 9, 1999. A PCT patent has been filed on July 7, 2000.

Patent Attorney :
Cabinet Lavoix, Paris, France

Novelty and Benefits :

- Increase in the accuracy of predicting and diagnosing Alzheimer Disease

- The technology can easily be developed as an easy to store, easy to use kit.

Additional information is available upon request.

Contact .

Marjory Hunt, PhD
tel: +41-21-314-4958
fax: +41-21-314-4957

Pactt
Office of Technology Transfer
University of Lausanne and University Hospitals

21, Rue du Bugnon
CH -1005 Lausanne
e-mail : marjory.hunt@hospvd.ch

Method for the Diagnosis of Alzheimer Disease and Therapeutic Composition

(Ref. Number IDF 12.01)

The Technology :
The technology relates to a method of predicting an increased risk, and a method of diagnosis for late-onset Alzheimer Disease.

The method consists in assaying a sample for the allele of the gene coding for the protein of interest and assaying the plasmatic level of the two proteins of interest.

The technology also proposes a therapeutic method for the prevention and treatment of Alzheimer Disease

Applications :
Prognosis, diagnosis and treatment of Alzheimer Disease